Trial site
Vitamed Galaj i Cichomski sp.j.
Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-079, PolandEU-13 widening countryNot linked to an institution yet
- 19running trials
- 22closed trials
The trials here
What the 42 trials at this site are about, from their registry records.
- Phase
- Phase 322 trials
- Phase 217 trials
- Phase 1/21 trial
- Phase 2/31 trial
- Phase 41 trial
- Status
- Completed21 trials
- Active, not recruiting11 trials
- Recruiting5 trials
- Not yet recruiting3 trials
- Suspended1 trial
- Terminated1 trial
- Lead sponsor
- Hoffmann-La Roche8 trials
- AbbVie5 trials
- Avalyn Pharma Inc.2 trials
- Bristol-Myers Squibb Services Unlimited Company2 trials
- Chiesi Farmaceutici S.p.A.2 trials
- and 23 more
Running trials
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Bristol-Myers Squibb· Source
Not yet recruiting
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
NCT07513181· Phase 2· Athos Therapeutics Inc· Source
Recruiting
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT07230288· Phase 2· AbbVie· Source
Recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
NCT07284459· Phase 2· Contineum Therapeutics· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
2024-512914-16-00· Phase 3· Amgen Inc.· Source
Recruiting
An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled
Antifibrotic Agent
2024-518289-28-00· Phase 2· Avalyn Pharma Inc.· Source
Active, not recruiting
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343· Phase 3· Amgen· Source
Active, not recruiting
A trial to evaluate efficacy and safety of buloxibutid in people with idiopathic pulmonary fibrosis
2023-509069-19-00· Phase 2· Vicore Pharma AB· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
2023-503699-25-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
2023-503697-21-01· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Recruiting
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
NCT06094010· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586023· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
NCT04639050· Phase 1/2· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135· Phase 3· AbbVie· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.
2023-507705-34-00· Phase 3· Alvotech Swiss AG· Source
Completed
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)
2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source
Completed
A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain
NCT06379893· Phase 4· HALEON· Source
Completed
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis
2023-503522-40-01· Phase 2· Anaptysbio Inc.· Source
Active, not recruiting
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)
2023-506183-13-00· Phase 2· F. Hoffmann-La Roche AG· Source
Completed
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313· Phase 3· AbbVie· Source
Completed
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT06132256· Phase 2· Syndax Pharmaceuticals· Source
Completed
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis
2022-503005-38-00· Phase 2· Landos Biopharma Inc.· Source
Completed
Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).
NCT06264674· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Completed
Efficacy and safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund maintenance therapy
2022-502208-64-00· Phase 2· Chiesi Farmaceutici S.p.A.· Source
Completed
A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and how safe it is compared to a licensed treatment called Entyvio®.
2022-502778-18-00· Phase 3· Polpharma Biologics S.A.· Source
Terminated
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source
Completed
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· Phase 3· AbbVie· Source
Completed
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
NCT05483907· Phase 2· Bridge Biotherapeutics, Inc.· Source
Completed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642· Phase 3· Hoffmann-La Roche· Source
Completed
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935· Phase 3· Celgene· Source
Completed
Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis
2024-515964-30-00· Phase 2· Avalyn Pharma Inc.· Source
Completed
A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion in Pediatric Subjects with Moderate to Severe Plaque Psoriasis
2024-520057-20-00· Phase 2· Bausch Health Americas Inc.· Source
Completed
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136· Phase 3· AbbVie· Source
Completed
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
NCT04609878· Phase 3· AstraZeneca· Source
Completed
Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories
NCT04469686· Phase 3· Cristcot HCA LLC· Source
Completed
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
NCT03283085· Phase 3· Shire· Source
Report an error